BioCentury
ARTICLE | Company News

Bamboo, Pfizer deal

August 8, 2016 7:00 AM UTC

Pfizer acquired the 78% of Bamboo it did not already own for $150 million up front and up to $495 million in development, regulatory and commercialization milestones. In 1Q16, the pharma obtained a 22% stake in Bamboo for about $43 million. Bamboo develops adeno-associated viral vector (AAV)-based gene therapies that preferentially target tissues affected by CNS and neuromuscular disorders.

The company spun out of gene therapy company Asklepios BioPharmaceutical Inc. (Chapel Hill, N.C.) in 2015 with an initial focus on BMB-D001, a systemic gene therapy for Duchenne muscular dystrophy (DMD) that is due to enter a Phase I trial this half. BMB-D001 is a recombinant adeno-associated virus serotype 9 (rAAV9) vector delivering a shortened, but functional copy of the dystrophin gene. ...